论文部分内容阅读
目的比较老年慢性心力衰竭患者治疗前后血浆脑利钠肽水平。方法选取医院收治的老年慢性心力衰竭患者41例作为观察组,给予抗心力衰竭治疗,另选择同期门诊健康体检者41例作为对照组,比较2组血浆脑利钠肽水平、左室射血分数变化情况,观察观察组治疗效果并对其进行半年随访,统计再次入院率。结果 41例患者,显效18例,有效20例,无效3例,总有效率为92.68%(38/41),对患者进行半年随访,其再次入院率36.59%(15/41)。治疗前后,观察组血浆脑利钠肽水平比较差异有统计学意义(P<0.01);且治疗后观察组血浆脑利钠肽水平为(92.5±22.5)ng/L,高于对照组的(78.4±6.6)ng/L(P<0.05)。观察组左室射血分数为(45.4±5.4)%,低于对照组的(62.8±10.3)%(P<0.01)。结论血浆脑利钠肽水平能够客观反映慢性心力衰竭患者心功能状态,属于诊断心力衰竭的敏感性指标,而抗心力衰竭治疗,可显著改善患者血浆脑利钠肽水平,值得临床推广。
Objective To compare the levels of plasma brain natriuretic peptide in elderly patients with chronic heart failure before and after treatment. Methods Forty-one elderly patients with chronic heart failure admitted to hospital were selected as the observation group and received anti-heart failure treatment. Another 41 healthy subjects were selected as the control group. The levels of plasma brain natriuretic peptide, left ventricular ejection fraction Changes observed the observation group treatment effect and its six months follow-up, statistics, re-admission rate. Results In 41 patients, markedly effective in 18 cases, effective in 20 cases and ineffective in 3 cases, the total effective rate was 92.68% (38/41). The patients were followed up for half a year and the rate of re-admission was 36.59% (15/41). The levels of plasma brain natriuretic peptide in the observation group before and after treatment were significantly different (P <0.01). After treatment, the level of plasma brain natriuretic peptide in the observation group was (92.5 ± 22.5) ng / L, higher than that in the control group 78.4 ± 6.6) ng / L (P <0.05). The left ventricular ejection fraction in the observation group was (45.4 ± 5.4)%, which was lower than that in the control group (62.8 ± 10.3)% (P <0.01). Conclusion The level of plasma brain natriuretic peptide can objectively reflect the state of heart function in patients with chronic heart failure and is a sensitive index for diagnosing heart failure. However, the treatment of heart failure can significantly improve the level of plasma brain natriuretic peptide, which is worthy of clinical promotion.